Market Analysis and Insights:- Global Lennox-Gastaut Syndrome Drug Market
Global Lennox-Gastaut Syndrome Drug Market By Mechanism of Action (Anti-Epileptics, Anticonvulsants and Others), Drugs (Valproic Acid, Topiramate, Felbamate, Rufinamide, Lamotrigine and Others), Treatment (Medication, Dietary Therapy and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026
Market Analysis: Global Lennox-Gastaut Syndrome Drug Market
Global Lennox-Gastaut syndrome drug market is growing at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the rising population with risk factors for LGS, the growing prevalence of infectious diseases such as encephalitis and meningitis will further increase the risk of the development of LGS, initiatives taken by government and non-governmental organizations for raising awareness about this syndrome, increasing investment of biotechnology and pharmaceutical industries in R&D and increasing healthcare expenditure are some of the factors fueling the market growth.
Get More Insight About the Global Lennox-Gastaut Syndrome Drug Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-lennox-gastaut-syndrome-drug-market
Market Definition: Global Lennox-Gastaut Syndrome Drug Market
Lennox-Gastaut syndrome (LGS) is a rare type of childhood onset epilepsy that progresses during early stages of childhood. Patients with this syndrome have developmental delay, behavioral problems and different types of seizures such as atonic, tonic and atypical absence seizures.
This syndrome is associated with several gene mutations, perinatal insults, congenital infections, brain tumors/malformations and genetic disorders such as tuberous sclerosis and West syndrome.
According to National Organization for Rare Disorders (NORD), it estimates that Lennox-Gastaut syndrome occur in 1-28 people per 100,000 and it accounts for 1-4 percent of all cases of childhood epilepsy. The annual incidence of this syndrome in children is estimated to be 2 per 100,000 children.
Market Drivers
- Rising population with risk factors for LGS is driving the market growth
- Growing prevalence of infectious diseases such as encephalitis and meningitis increases the risk of the development of LGS which acts as a market driver
- Increasing investment of biotechnology and pharmaceutical industries in R&D is enhancing the market growth
- Initiatives taken by government and non-governmental organizations for raising awareness amongst people about this disorder also boost the market growth
- Increasing global healthcare expenditure drives the market growth
Market Restraints
- Side effects associated with available treatment is hampering the market growth
- High cost of treatment available is restraining the market growth
- Lack of availability of essential services in remote areas acts as a market restraint
Know More About this Report @ https://www.databridgemarketresearch.com/reports/global-lennox-gastaut-syndrome-drug-market
Segmentation: Global Lennox-Gastaut Syndrome Drug Market
By Mechanism of Action
- Anti-Epileptics
- Anticonvulsants
- Others
By Drugs
- Valproic Acid
- Topiramate
- Felbamate
- Rufinamide
- Lamotrigine
- Others
By Treatment
- Medication
- Dietary Therapy
- Surgery
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- U.K.
- France
- Spain
- Netherlands
- Belgium
- Switzerland
- Turkey
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Rest of Asia Pacific
- South America
- Brazil
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Key Developments in the Market
- In November 2018, Aquestive Therapeutics, Inc received the U.S FDA approval for Sympazan (clobazam) for the treatment of Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older. Patients with LGS have difficulty in swallowing tablets or large volumes of oral suspension, because of physical limitations or compliance issues, Sympazan oral film is a cost effective treatment and will overcome difficulties in those patients who faces difficulty in swallowing tablets
- In June 2018, GW Pharmaceuticals plc received the U.S FDA approval for Epidiolex (cannabidiol), oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. This approval proves that properly evaluating the active ingredients contained in marijuana can lead to important medical therapies
Competitive Analysis:
Global Lennox-Gastaut syndrome drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Lennox-Gastaut syndrome drug for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
The key market players in the global Lennox-Gastaut syndrome drug market are Pfizer Inc, Sunovion Pharmaceuticals Inc, Novartis AG, Abbott, Eisai Co., Ltd, INSYS THERAPEUTICS, INC, GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S, Bausch Health, Supernus Pharmaceuticals, Inc, UCB Pharma Ltd, Sanofi, Marinus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd among others.
Research Methodology: Global Lennox-Gastaut Syndrome Drug Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-lennox-gastaut-syndrome-drug-market
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Access Full Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-lennox-gastaut-syndrome-drug-market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Market Analysis and Insights:- Global Lennox-Gastaut Syndrome Drug MarketGlobal Lennox-Gastaut Syndrome Drug Market By Mechanism of Action (Anti-Epileptics, Anticonvulsants and Others), Drugs (Valproic Acid, Topiramate, Felbamate, Rufinamide, Lamotrigine and Others), Treatment (Medication, Dietary Therapy and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026 Market Analysis: Global Lennox-Gastaut Syndrome Drug MarketGlobal Lennox-Gastaut syndrome drug market is growing at a substantial CAGR in the forecast period of 2019-2026.
This rise in market value can be attributed to the rising population with risk factors for LGS, the growing prevalence of infectious diseases such as encephalitis and meningitis will further increase the risk of the development of LGS, initiatives taken by government and non-governmental organizations for raising awareness about this syndrome, increasing investment of biotechnology and pharmaceutical industries in R and increasing healthcare expenditure are some of the factors fueling the market growth.Get More Insight About the Global Lennox-Gastaut Syndrome Drug Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-lennox-gastaut-syndrome-drug-market Market Definition: Global Lennox-Gastaut Syndrome Drug MarketLennox-Gastaut syndrome (LGS) is a rare type of childhood onset epilepsy that progresses during early stages of childhood.
Patients with this syndrome have developmental delay, behavioral problems and different types of seizures such as atonic, tonic and atypical absence seizures.This syndrome is associated with several gene mutations, perinatal insults, congenital infections, brain tumors/malformations and genetic disorders such as tuberous sclerosis and West syndrome.According to National Organization for Rare Disorders (NORD), it estimates that Lennox-Gastaut syndrome occur in 1-28 people per 100,000 and it accounts for 1-4 percent of all cases of childhood epilepsy.
The annual incidence of this syndrome in children is estimated to be 2 per 100,000 children.Market DriversRising population with risk factors for LGS is driving the market growthGrowing prevalence of infectious diseases such as encephalitis and meningitis increases the risk of the development of LGS which acts as a market driverIncreasing investment of biotechnology and pharmaceutical industries in R is enhancing the market growthInitiatives taken by government and non-governmental organizations for raising awareness amongst people about this disorder also boost the market growthIncreasing global healthcare expenditure drives the market growthMarket RestraintsSide effects associated with available treatment is hampering the market growthHigh cost of treatment available is restraining the market growthLack of availability of essential services in remote areas acts as a market restraintKnow More About this Report @ https://www.databridgemarketresearch.com/reports/global-lennox-gastaut-syndrome-drug-market Segmentation: Global Lennox-Gastaut Syndrome Drug MarketBy Mechanism of ActionAnti-EpilepticsAnticonvulsantsOthersBy DrugsValproic AcidTopiramateFelbamateRufinamideLamotrigineOthersBy TreatmentMedicationDietary TherapySurgeryBy Route of AdministrationOralParenteralBy Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyBy End-UsersHospitalsHomecareSpecialty ClinicsBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia PacificSouth AmericaBrazilRest of South AmericaMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the MarketIn November 2018, Aquestive Therapeutics, Inc received the U.S FDA approval for Sympazan (clobazam) for the treatment of Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.
Patients with LGS have difficulty in swallowing tablets or large volumes of oral suspension, because of physical limitations or compliance issues, Sympazan oral film is a cost effective treatment and will overcome difficulties in those patients who faces difficulty in swallowing tabletsIn June 2018, GW Pharmaceuticals plc received the U.S FDA approval for Epidiolex (cannabidiol), oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older.
The report includes market shares of Lennox-Gastaut syndrome drug for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Players:The key market players in the global Lennox-Gastaut syndrome drug market are Pfizer Inc, Sunovion Pharmaceuticals Inc, Novartis AG, Abbott, Eisai Co., Ltd, INSYS THERAPEUTICS, INC, GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S, Bausch Health, Supernus Pharmaceuticals, Inc, UCB Pharma Ltd, Sanofi, Marinus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd among others.Research Methodology: Global Lennox-Gastaut Syndrome Drug MarketData collection and base year analysis is done using data collection modules with large sample sizes.
Market Analysis and Insights:- Global Chronic Depressive Personality Disorder Treatment MarketGlobal Chronic Depressive Personality Disorder Treatment Market By Mechanism of Action (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)), Drugs (Amitriptyline, Bupropion, Sertraline, Duloxetine), Diagnosis (Physical Exam, Lab Tests and Psychological Evaluation), Treatment (Medication and Psychotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026 Market Analysis: Global Chronic Depressive Personality Disorder Treatment MarketGlobal chronic depressive personality disorder treatment market is growing at a steady CAGR in the forecast period of 2019-2026.
The report contains data of the base year 2018 and historic year 2017.
This rise in market value can be attributed to the increasing prevalence of depressive personality disorder, increase in diagnosis, requirement for long term treatment and increase in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conference are some factors fueling the market growth.Market Definition: Global Chronic Depressive Personality Disorder Treatment MarketChronic depressive personality disorder is also known as dysthymia is a form of depression which is mild but continuously remains for several years.
A patient with chronic depressive personality disorder have symptoms such as lost interest in normal activities, hopelessness, low self-esteem, low appetite, low energy and an overall feeling of inadequacy.
These feelings interfere with the patient’s personal and social relationship, profession and daily activities.
This disorder can affect children and adolescents, approximately 11.2% of 13 to 18 years olds gets affected by this disorder at some point during their lives and girls are more likely to experience this disorder than boys.Market DriversIncreasing prevalence of chronic depressive personality disorder is driving the market growthIncrease in diagnosis of chronic depressive personality disorder also acts as a market driverLong term treatment requirement is accelerating the growth if this marketIncrease in initiatives by government and non-government organizations regarding mental disorders by awareness campaigns and conferences is also boosting the market growthMarket RestraintsEffectiveness of psychotherapy alone is hindering the market growthLack of approved drug for chronic depressive personality disorder is restraining the market growthNon-medicated treatments are available for this disorder which acts as a market restraintSegmentation: Global Chronic Depressive Personality Disorder Treatment MarketBy Mechanism of ActionSelective Serotonin Reuptake Inhibitors (SSRIs)Tricyclic Antidepressants (TCAs)Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)By DrugsAmitriptylineBupropionSertralineDuloxetineBy DiagnosisPhysical ExamLab TestsPsychological EvaluationBy TreatmentMedicationPsychotherapyBy Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyBy End-UsersHospitalsHomecareSpecialty ClinicsBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesRest of Asia PacificSouth AmericaBrazilRest of South AmericaMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the MarketIn March 2019, Johnson & Johnson Services, Inc received the U.S FDA approval for Spravato (esketamine), nasal spray for use in patients with treatment-resistant depression (TRD) a type of major depressive disorder (MDD).
Filgrastim Biosimilars Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the filgrastim biosimilars industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected filgrastim biosimilars market growth numbers 2021-2030.View Complete Report:https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilars-global-marketThe Filgrastim Biosimilars Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global filgrastim biosimilars market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Filgrastim Biosimilars Global Market Report 2021 covers filgrastim biosimilars market drivers, filgrastim biosimilars market trends, filgrastim biosimilars market growth rate, filgrastim biosimilars market major players, player-adopted strategies in the market, and filgrastim biosimilars market size.The global filgrastim biosimilars market is expected to grow from $0.72 billion in 2020 to $0.77 billion in 2021 at a compound annual growth rate (CAGR) of 6.9%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
The filgrastim biosimilars market is expected to reach $1.04 billion in 2025 at a CAGR of 8%.Request For The Sample Now:https://www.thebusinessresearchcompany.com/sample.aspx?id=4016=smpThe report covers the filgrastim biosimilars market segments-1) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy3) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing OrganizationAbout The Business Research Company: The Business Research Company is a market intelligence firm that excels in company, market, and consumer research.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
